These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31610404)

  • 1. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
    J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P; Capobianco M; Moiola L; Patti F; Frau J; Uccelli A; Centonze D; Perini P; Tortorella C; Prosperini L; Lus G; Fuiani A; Falcini M; Martinelli V; Comi G; Ghezzi A
    J Neurol; 2016 Sep; 263(9):1727-35. PubMed ID: 27286847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México.
    Casallas-Vanegas A; Gomez-Figueroa E; de Saráchaga AJ; Zabala-Angeles I; García-Estrada C; Salado-Burbano JC; DiazGranados-Palacio MC; Corona-Vázquez T; de Jesús Flores-Rivera J; Rivas-Alonso V
    J Neurol Sci; 2020 Dec; 419():117204. PubMed ID: 33161302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring B cell depletion therapy in MS according to memory B cell monitoring.
    Novi G; Bovis F; Fabbri S; Tazza F; Gazzola P; Maietta I; Currò D; Bruschi N; Roccatagliata L; Boffa G; Lapucci C; Pesce G; Cellerino M; Solaro C; Laroni A; Capello E; Mancardi G; Sormani M; Inglese M; Uccelli A
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32753406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
    Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
    Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
    Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.
    Shi B; Zhao M; Qiao L; Huang F; Zhou S; Wei Y; Wang J; Wang N
    Mult Scler Relat Disord; 2021 Sep; 54():103143. PubMed ID: 34273608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America.
    Rojas JI; López PA; Criniti J; Pettinicchi JP; Caride A; Correa Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Andrade JSP; Daccach Marques V; Bribiesca Contreras E; Gómez Figueroa E; Flores Rivera J; Galleguillos L; Navas C; Soares Neto HR; Gracia F; Cristiano E; Patrucco L; Becker J; Hamuy F; Alonso R; Man F; Tkachuk V; Nadur D; Lana-Peixoto M; Castillo IS; Carnero Contentti E
    Mult Scler Relat Disord; 2023 Mar; 71():104508. PubMed ID: 36738691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
    J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.